Get the Stockscreener App
4.75
5.32%
0.24
After Hours:
4.85
0.10
+2.11%
Helus Pharma Inc stock is traded at $4.75, with a volume of 699.73K.
It is up +5.32% in the last 24 hours and down -38.23% over the past month.
Helus Pharma Inc is a clinical-stage pharmaceutical company developing proprietary novel serotonergic agonists (NSAs), which are synthetic molecules designed to activate serotonin pathways associated with neuroplasticity. These compounds are being investigated for potential use in the treatment of depression, anxiety, and other mental health conditions, areas where there is an unmet medical need. It aims to provide treatments designed for mental health disorders. The company is currently developing HLP003, a proprietary NSA, in Phase 3 clinical development for the adjunctive treatment of substantial depressive disorder. It operates in Canada, the United States, the United Kingdom, and Ireland.
See More
Previous Close:
$4.51
Open:
$4.61
24h Volume:
699.73K
Relative Volume:
1.10
Market Cap:
$237.00M
Revenue:
-
Net Income/Loss:
$-122.31M
P/E Ratio:
-1.052
EPS:
-4.5151
Net Cash Flow:
$-110.41M
1W Performance:
+0.00%
1M Performance:
-38.23%
6M Performance:
+0.00%
1Y Performance:
+0.00%
1-Day Range:
$4.60
$4.825
1-Week Range:
$4.41
$4.95
52-Week Range:
$4.41
$8.5498
Helus Pharma Inc Stock (HELP) Company Profile
Compare HELP vs VRTX, REGN, ALNY, ARGX, INSM
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
HELP
Helus Pharma Inc
|
4.75 | 225.02M | 0 | -122.31M | -110.41M | -4.5151 |
VRTX
Vertex Pharmaceuticals Inc
|
454.97 | 113.96B | 12.07B | 3.95B | 3.19B | 15.33 |
REGN
Regeneron Pharmaceuticals Inc
|
749.47 | 78.41B | 14.34B | 4.50B | 3.77B | 41.56 |
ALNY
Alnylam Pharmaceuticals Inc
|
328.70 | 40.85B | 3.71B | 313.75M | 465.38M | 2.2571 |
ARGX
Argen X Se Adr
|
697.05 | 42.05B | 4.16B | 1.29B | 734.26M | 19.58 |
INSM
Insmed Inc
|
148.31 | 29.99B | 606.42M | -1.28B | -997.58M | -6.403 |
Helus Pharma Inc Stock (HELP) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Feb-02-26 | Initiated | Jefferies | Buy |
| Mar-13-25 | Initiated | Guggenheim | Buy |
| Nov-19-21 | Downgrade | Maxim Group | Buy → Hold |
Helus Pharma Inc Stock (HELP) Latest News
Cybin Inc (HELP) reports positive phase 2 anxiety study data - MSN
Cybin Inc (HELP) Reports Positive Phase 2 Anxiety Study Data - Insider Monkey
Helus Pharma appoints Michael Cola as CEO - MSN
symbol__ Stock Quote Price and Forecast - CNN
HELP Stock Price, Quote & Chart | CYBIN INC (NASDAQ:HELP) - ChartMill
Help stock crashes on anxiety trial results, but here’s why Jefferies sees up to 200% upside - MSN
Helus Pharma reports encouraging Phase 2 results for HLP004 anxiety treatment - MSN
Helus Pharma (CYBN) appoints Jill Conwell as Chief People Officer - Stock Titan
Helus Pharma Strengthens Executive Team with Appointment of Jill Conwell as Chief People Officer - Bitget
Helus Pharma Adds Chief People Officer as Mental Health Pipeline Advances - TipRanks
CNS Drug Developers Add Pharma Veterans as Sector Nears First FDA Decisions - Investing News Network
Neuropsychiatric Innovation Draws Big Pharma Interest and Fresh Investment - Baystreet.ca
HELP Stock Price and Chart — NEO:HELP - TradingView
Weekly Roundup on the Cannabis Sector & Psychedelic Sector - marketexclusive.com
Assessing Cybin (HELP) Valuation After HLP004 Phase 2 Anxiety Data Draws Fresh Attention - simplywall.st
Psychedelic: Helus Pharma reports HLP004 Phase 2 signal detection study results - Yahoo Finance
Cybin (HELP) Is Down 27.3% After Positive HLP004 GAD Phase 2 Data Reported Is The Thesis Intact? - Yahoo Finance
Helus Pharma Announces Topline Results in Phase 2 Signal Detection Study for HLP004 in Patients with Generalized Anxiety Disorder - Sahm
Could Helus Pharma’s HLP004 Data Quietly Reframe Cybin’s (HELP) Interventional Psychiatry Investment Story? - simplywall.st
HELP Stock Crashes On Anxiety Trial Results, But Here’s Why Jefferies Sees Up To 200% Upside - Asianet Newsable
HELP Stock Tanks 22% Despite Strong Phase 2 Results For Anxiety Treatment: Retail Buys The Dip Ignoring Market’s Pessimism - Stocktwits
Helus Pharma’s top-line Phase II data signal detection study for HLP004 - The Pharma Letter
Jefferies reiterates Helus Pharma stock rating on anxiety data By Investing.com - Investing.com Canada
Agencia de ComunicacãoHelus Pharma Announces Topline Results in Phase 2 Signal Detection Study for HLP004 in Patients with Generalized Anxiety Disorder - Estadão Blue Studio
Helus Pharma Stock Tumbles As Anxiety Drug Study DisappointsHelus Pharma (NASDAQ:HELP) - Benzinga
Helus Pharma (HELP) Shares Drop Despite Positive Phase 2 Trial R - GuruFocus
Helus Pharma (HELP) Reports Positive Phase 2 Study Results for A - GuruFocus
Cybin’s Helus Pharma Posts Strong Phase 2 Data for HLP004 in Hard-to-Treat Anxiety - TipRanks
Helus stock falls on data for anxiety therapy (HELP:NASDAQ) - Seeking Alpha
Helus Pharma announces topline results in phase 2 signal detection study for Hlp004 in patients with generalized anxiety disorder - marketscreener.com
Helus Pharma Announces Topline Results In Phase 2 Signal Detection Study For Hlp004 In Patients With Generalized Anxiety Disorder - TradingView
Helus Pharma (HELP) Price Target Raised by HC Wainwright & Co. | - GuruFocus
Psychedelic Biotechs Push Toward Phase 3: Five Companies Advancing CNS Treatments - The AI Journal
Psychedelic Medicine Advances: Here Are Five Companies Targeting CNS Disorders - The Malaysian Reserve
From Lab to Clinic: Five CNS Companies Advancing Neuroscience Treatments - Baystreet.ca
Helus Pharma appoints Dr. Freda Lewis-Hall to board of directors - Investing.com India
HELUS Pharma: Transitioning From Psychedelic Research To Late-Stage Clinical Neuroscience - Seeking Alpha
Helus Pharma (Nasdaq: HELP) brings former Pfizer CMO Lewis-Hall onto board - Stock Titan
Helus Pharma appoints Dr. Freda Lewis-Hall to board of directors By Investing.com - Investing.com South Africa
Helus Pharma Inc Stock (HELP) Financials Data
Revenue
Net Income
Cash Flow
EPS
1.82%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):